Anaemia and renal dysfunction in chronic heart failure

van der Meer, Peter; van Veldhuisen, Dirk J.
November 2009
Heart;Nov2009, Vol. 92 Issue 21, p18
Academic Journal
The article focuses on the associative roles of renal disorder and anaemia to chronic heart disease. Study shows that impaired renal function can lead to anaemia which is a manifestation that a patient suffers from chronic heart failure. Moreover, excessive increase of haemoglobin in anaemic patients will result in higher death rate.


Related Articles

  • Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure. Fishbane, Steven; Miyawaki, Nobuyuki // Kidney International;Feb2010, Vol. 77 Issue 3, p175 

    Anemia is common in chronic kidney disease (CKD). The CHOIR study found increased risk of a composite cardiovascular outcome when anemia was treated with epoetin-alfa to a target hemoglobin level of 13.5 as compared with 11.3 g/dl. Whether this increase applies to all patient subgroups equally...

  • Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Hogenhuis, Jochem; Voors, Adriaan A.; Jaarsma, Tiny; Hoes, Arno W.; Hillege, Hans L.; Kragten, Johannes A.; van Veldhuisen, Dirk J. // European Journal of Heart Failure;Aug2007, Vol. 9 Issue 8, p787 

    Abstract: Background: Anaemia may affect B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) levels, but this has not been well described in heart failure (HF) patients without the exclusion of patients with renal dysfunction. Aims: To study the influence of both anaemia and renal...

  • Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Leaf, David E.; Goldfarb, David S. // Kidney International;Jan2009, Vol. 75 Issue 1, p15 

    Recent evidence suggests that targeting higher hemoglobin values with erythropoiesis stimulating agents (ESAs) may lack mortality benefits and may even result in adverse cardiovascular complications when used in chronic kidney disease patients. However, ESAs are frequently reported to result in...

  • Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Canaud, Bernard; Mingardi, Giulio; Braun, Johann; Aljama, Pedro; Kerr, Peter G.; Locatelli, Francesco; Villa, Giuseppe; Vlem, Bruno Van; McMahon, Alan W.; Kerlöeguen, Cécile; Beyer, Ulrich // Nephrology Dialysis Transplantation;Nov2008, Vol. 23 Issue 11, p3654 

    Background. Extending the administration interval of erythropoiesis-stimulating agents (ESAs) represents an opportunity to improve the efficiency of anaemia management in patients with chronic kidney disease (CKD). However, effective haemoglobin (Hb) maintenance can be challenging with epoetin...

  • Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. Portolés, José M.; de Francisco, Ángel L. M.; Górriz, José L.; Martínez-Castelao, Alberto; López-Gómez, Juan M.; Arias, Manuel; de la Cruz, Juan J.; Cases, Aleix; Fernández, Evaristo; Aljama, Pedro // Kidney International Supplement;Dec2008, Issue 111, pS82 

    Maintenance of target hemoglobin (Hb) values in hemodialysis patients treated with erythropoiesis-stimulating agents (ESAs) remains difficult. We examined Hb variability in the clinical setting in hemodialysis patients. Hemodialysis patients treated with ESAs who maintained the recommended Hb...

  • The importance of correction of anemia with erythropoietin and intravenous iron in severe resistant congestive heart failure. Wexler, Dov; Silverberg, Don; Sheps, David; Iaina, Adrian // European Journal of Heart Failure. Supplements;Jun2003, Vol. 2 Issue 2, p225 

    About one third to one half of patients with heart failure are anemic, in that they have a hemoglobin level of less than 12 g/dL. Anemia is more common and more severe as the clinical status of CHF worsens. In addition, anemia is associated with a higher mortality and higher rate of...

  • A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. Pfeffer, Marc A.; Burdmann, Emmanuel A.; Chen, Chao-Yin; Cooper, Mark E.; De Zeeuw, Dick; Eckardt, Kai-Uwe; Feyzi, Jan M.; Ivanovich, Peter; Kewalramani, Reshma; Levey, Andrew S.; Lewis, Eldrin F.; McGill, Janet B.; McMurray, John J.V.; Parfrey, Patrick; Parving, Hans-Henrik; Remuzzi, Giuseppe; Singh, Ajay K.; Solomon, Scott D.; Toto, Robert // New England Journal of Medicine;11/19/2009, Vol. 361 Issue 21, p2019 

    Background: Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been...

  • Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. Singh, Ajay K.; Szczech, Lynda; Tang, Kezhen L.; Barnhart, Huiman; Sapp, Shelly; Wolfson, Marsha; Reddan, Donal // New England Journal of Medicine;11/16/2006, Vol. 355 Issue 20, p2085 

    Background: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin...

  • What should the optimal target hemoglobin be?1. Gómez, Juan M. López; Carrera, Fernando // Kidney International Supplement;May2002, Issue 80, p39 

    What should the optimal target hemoglobin be? Partial correction of anemia in patients with chronic kidney disease (CKD) improves anemia-related symptoms. However, controversy remains as to whether total correction of anemia provides benefits over and above those afforded by partial correction....


Read the Article


Sign out of this library

Other Topics